Vascular endothelial growth factor and dexamethasone release from nonfouling sensor coatings affect the foreign body response.
暂无分享,去创建一个
W M Reichert | W. Reichert | L. Norton | N. Wisniewski | B. Klitzman | B Klitzman | L W Norton | H E Koschwanez | N A Wisniewski | H. Koschwanez
[1] W M Reichert,et al. Engineering the tissue which encapsulates subcutaneous implants. I. Diffusion properties. , 1997, Journal of biomedical materials research.
[2] D. Bigner,et al. Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity , 2005, Leukemia & lymphoma.
[3] W Kenneth Ward,et al. Vascularizing the tissue surrounding a model biosensor: how localized is the effect of a subcutaneous infusion of vascular endothelial growth factor (VEGF)? , 2003, Biosensors & bioelectronics.
[4] D. Mooney,et al. Polymeric system for dual growth factor delivery , 2001, Nature Biotechnology.
[5] Joan W. Miller,et al. VEGF164-mediated Inflammation Is Required for Pathological, but Not Physiological, Ischemia-induced Retinal Neovascularization , 2003, The Journal of experimental medicine.
[6] Buddy D Ratner,et al. Biomaterials: where we have been and where we are going. , 2004, Annual review of biomedical engineering.
[7] A. Mantovani,et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. , 1996, Blood.
[8] K. Olbrich,et al. Long- and short-term effects of biological hydrogels on capsule microvascular density around implants in rats. , 2001, Journal of biomedical materials research.
[9] H. Schieffer,et al. Five‐Year Follow‐Up of a Bipolar Steroid‐Eluting Ventricular Pacing Lead , 1999, Pacing and clinical electrophysiology : PACE.
[10] N Wisniewski,et al. Characterization of implantable biosensor membrane biofouling , 2000, Fresenius' journal of analytical chemistry.
[11] Peter G Jacobs,et al. Feasibility of continuous long-term glucose monitoring from a subcutaneous glucose sensor in humans. , 2004, Diabetes technology & therapeutics.
[12] F. Bosman,et al. Immunohistochemical Expression of Endothelial Markers CD31, CD34, von Willebrand Factor, and Fli-1 in Normal Human Tissues , 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[13] P. Abel,et al. Assessment of subcutaneous glucose concentration: validation of the wick technique as a reference for implanted electrochemical sensors in normal and diabetic dogs , 1987, Diabetologia.
[14] P F Morrison,et al. Steady-state theory for quantitative microdialysis of solutes and water in vivo and in vitro. , 1990, Life sciences.
[15] F. Gaytán,et al. Selective Apoptosis of Luteal Endothelial Cells in Dexamethasone-Treated Rats Leads to Ischemic Necrosis of Luteal Tissue1 , 2002, Biology of reproduction.
[16] N. Wisniewski,et al. Decreased analyte transport through implanted membranes: differentiation of biofouling from tissue effects. , 2001, Journal of biomedical materials research.
[17] K. Sayama,et al. So-called biological dressing effects of cultured epidermal sheets are mediated by the production of EGF family, TGF-beta and VEGF. , 2003, Journal of dermatological science.
[18] Ciro Indolfi,et al. Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents. , 2003, Trends in cardiovascular medicine.
[19] G. Randolph,et al. Migration of leukocytes across endothelium and beyond: molecules involved in the transmigration and fate of monocytes , 1999, Journal of leukocyte biology.
[20] H Peter Chase,et al. The role of continuous glucose sensors in diabetes care. , 2004, Endocrinology and metabolism clinics of North America.
[21] E J Topol,et al. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. , 1997, Journal of the American College of Cardiology.
[22] U. Ungerstedt,et al. Long-term continuous glucose monitoring with microdialysis in ambulatory insulin-dependent diabetic patients , 1993, The Lancet.
[23] M. Tanihara,et al. Sustained release of basic fibroblast growth factor and angiogenesis in a novel covalently crosslinked gel of heparin and alginate. , 2001, Journal of biomedical materials research.
[24] A. Mikos,et al. Angiogenesis with biomaterial-based drug- and cell-delivery systems , 2004, Journal of biomaterials science. Polymer edition.
[25] R. Lang,et al. VEGF deprivation-induced apoptosis is a component of programmed capillary regression. , 1999, Development.
[26] A. Ahluwalia,et al. The Microcirculation and Inflammation: Site of Action for Glucocorticoids , 2000, Microcirculation.
[27] R. Green,et al. Glucocorticoid-regulated VEGF expression in ischemic skeletal muscle. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[28] A. Perets,et al. Vascular endothelial growth factor-releasing scaffolds enhance vascularization and engraftment of hepatocytes transplanted on liver lobes. , 2005, Tissue engineering.
[29] S. Woodward. How Fibroblasts and Giant Cells Encapsulate Implants: Considerations in Design of Glucose Sensors , 1982, Diabetes Care.
[30] Mark Saltzman W,et al. Materials for protein delivery in tissue engineering. , 1998, Advanced drug delivery reviews.
[31] G. S. Wilson,et al. Biosensors for real-time in vivo measurements. , 2005, Biosensors & bioelectronics.
[32] David J. Mooney,et al. Polymeric Growth Factor Delivery Strategies for Tissue Engineering , 2003, Pharmaceutical Research.
[33] D. Dorsky,et al. Use of vascular endothelial cell growth factor gene transfer to enhance implantable sensor function in vivo. , 2003, Journal of biomedical materials research. Part A.
[34] J. Folkman,et al. The sequence of events in the regression of corneal capillaries. , 1978, Laboratory investigation; a journal of technical methods and pathology.
[35] W. Reichert,et al. Biomaterials community examines biosensor biocompatibility. , 2000, Diabetes technology & therapeutics.
[36] D. Dorsky,et al. Enhancement of implantable glucose sensor function in vivo using gene transfer-induced neovascularization. , 2005, Biomaterials.
[37] F Moussy,et al. In vivo evaluation of a dexamethasone/PLGA microsphere system designed to suppress the inflammatory tissue response to implantable medical devices. , 2002, Journal of biomedical materials research.
[38] D. Jackson. The unfolding tale of PECAM‐1 , 2003, FEBS letters.
[39] R. C. Johnson,et al. Neovascularization of synthetic membranes directed by membrane microarchitecture. , 1995, Journal of biomedical materials research.
[40] D. Vittet,et al. Differential expression of VEGF receptors in adrenal atrophy induced by dexamethasone: a protective role of ACTH. , 2003, American journal of physiology. Endocrinology and metabolism.
[41] James M. Anderson,et al. Biological Responses to Materials , 2001 .
[42] M. Langer,et al. Effect on intimal hyperplasia of dexamethasone released from coated metal stents compared with non-coated stents in canine femoral arteries , 1998, CardioVascular and Interventional Radiology.
[43] Tsuyoshi Saito,et al. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. , 2006, Endocrinology.
[44] E. Topol,et al. Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. , 1994, The Journal of clinical investigation.
[45] Julie Morris,et al. Assessment of Vascularity in Histological Sections: Effects of Methodology and Value as an Index of Angiogenesis in Breast Tumours , 1998, The Histochemical Journal.
[46] S. Putney. Encapsulation of proteins for improved delivery. , 1998, Current opinion in chemical biology.
[47] John J Mastrototaro,et al. Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring. , 1999, American journal of physiology. Endocrinology and metabolism.
[48] Susumu Ishida,et al. VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. , 2004, Investigative ophthalmology & visual science.
[49] D. Pode,et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.
[50] R. Kew,et al. Angiogenic factors stimulate mast-cell migration. , 1995, Blood.
[51] W M Reichert,et al. In vitro characterization of vascular endothelial growth factor and dexamethasone releasing hydrogels for implantable probe coatings. , 2005, Biomaterials.
[52] N. Wisniewski,et al. Water-soluble treatments to enhance glucose permeability of protein-resistant polymer overlayers , 2001, Journal of biomaterials science. Polymer edition.
[53] R M Smith,et al. Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin 1. , 1997, The Journal of clinical investigation.
[54] Jingtai Cao,et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. , 2004, The Journal of clinical investigation.